TxCell, a French biotechnology company developing cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, has appointed Damian Marron as Chief Executive. In addition, Francois Meyer, previously CEO and Chairman of the Board of TxCell become Executive Chairman.
Marron will guide the development of Ovasave, TxCell’s lead autologous Ag-Treg cell-based immunotherapy. Ovasave is currently in Phase II development for the treatment of Crohn’s disease.
'At this stage of TxCell’s development, it has been critical for us to appoint a CEO who has both a high level of experience at working in niche and orphan market places with unmet medical needs, as well as for both private and public companies,' said Meyer.
Previously, Marron was CEO of Cytheris, a clinical stage biotechnology company. Prior to this, he was CEO of Trophos from 2008 to 2012.
He has also been Executive Vice President, Corporate Development at NicOx and has held various business development and operational roles at 3M Pharmaceuticals, Orphan Europe, Rhone-Poulenc-Rorer and Glaxo.
